Page last updated: 2024-10-18

dihydroxyacetone and Protoporphyria, Erythropoietic

dihydroxyacetone has been researched along with Protoporphyria, Erythropoietic in 1 studies

Protoporphyria, Erythropoietic: An autosomal dominant porphyria that is due to a deficiency of FERROCHELATASE (heme synthetase) in both the LIVER and the BONE MARROW, the last enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features include mainly neurological symptoms, rarely cutaneous lesions, and elevated levels of protoporphyrin and COPROPORPHYRINS in the feces.

Research Excerpts

ExcerptRelevanceReference
"Patients with erythropoietic protoporphyria (EPP) are hypersensitive to long wave ultraviolet (UVA) radiation and visible light and they experience severe skin pain by light exposure."3.30Protection against visible light by dihydroxyacetone in erythropoietic protoporphyria. ( Heerfordt, IM; Lerche, CM; Philipsen, PA; Wulf, HC, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Heerfordt, IM1
Philipsen, PA1
Lerche, CM1
Wulf, HC1

Trials

1 trial available for dihydroxyacetone and Protoporphyria, Erythropoietic

ArticleYear
Protection against visible light by dihydroxyacetone in erythropoietic protoporphyria.
    Photodiagnosis and photodynamic therapy, 2023, Volume: 41

    Topics: Dihydroxyacetone; Humans; Light; Photochemotherapy; Photosensitivity Disorders; Photosensitizing Age

2023